The blood–brain barrier (BBB) is a dynamic interface responsible for maintaining the central
nervous system homeostasis. Its unique characteristics allow protecting the brain from …

Hemorrhagic transformation (HT) is a common complication of ischemic stroke that is
exacerbated by thrombolytic therapy. Methods to better prevent, predict, and treat HT are …

Ischemic stroke continues to be one of the most challenging diseases in translational
neurology. Tissue plasminogen activator (tPA) remains the only approved treatment for …

Neuroprotection for ischemic stroke refers to strategies, applied singly or in combination, that
antagonize the injurious biochemical and molecular events that eventuate in irreversible …

Neutrophils have key roles in ischemic brain injury, thrombosis, and atherosclerosis. As
such, neutrophils are of great interest as targets to treat and prevent ischemic stroke. After …

Background The free-radical–trapping agent NXY-059 showed promise as a
neuroprotectant in the Stroke–Acute Ischemic NXY Treatment I (SAINT I) trial, reducing …

Endovascular therapy is the first-line treatment for acute ischemic stroke. However, studies
have shown that, even with the timely opening of occluded blood vessels, nearly half of all …

Background NXY-059 is a free-radical–trapping agent that is neuroprotective in animal
models of stroke. We tested whether it would reduce disability in humans after acute …

del Zoppo GJ (University of Washington, Seattle, WA, USA). The neurovascular unit in the
setting of stroke (Review). J Intern Med 2010; 267: 156–171. Abstract. Microvessels and …

Background and Purpose—The neutral results of the SAINT II trial have again highlighted
difficulties translating neuroprotective efficacy from bench to bedside. Animal studies are …